[表皮生长因子受体突变与非小细胞肺癌的靶向治疗] - Suppr

Suppr

超能文献

[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].

作者信息

Lai Ren-Sheng, Xie Ling, Shen Long-Shu, He Ya-Min, Zhu Chang-Le

出版信息

Zhonghua Bing Li Xue Za Zhi. 2005 Nov;34(11):745-6.

PMID:16536324

Abstract

摘要

相似文献

[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].

Zhonghua Bing Li Xue Za Zhi. 2005 Nov;34(11):745-6.

EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.

Nat Clin Pract Oncol. 2006 Apr;3(4):170-1. doi: 10.1038/ncponc0476.

Optimising therapy for EGFR-addicted NSCLC: just the start.

Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2. Epub 2012 Jan 26.

Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.

Clin Lung Cancer. 2005 Nov;7(3):163-5. doi: 10.1016/S1525-7304(11)70404-1.

Targeting EGFR in non-small-cell lung cancer.

N Engl J Med. 2005 Jul 14;353(2):200-2. doi: 10.1056/NEJMe058113.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

Erlotinib or gefitinib for non-small-cell lung cancer.

N Engl J Med. 2011 Jun 16;364(24):2367; author reply 2368. doi: 10.1056/NEJMc1103918.

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.

Korean J Intern Med. 2016 Nov;31(6):1140-1149. doi: 10.3904/kjim.2015.062. Epub 2016 Mar 28.

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.

Adv Ther. 2011 Feb;28(2):126-33. doi: 10.1007/s12325-010-0096-4. Epub 2010 Dec 16.

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].

作者信息

Lai Ren-Sheng, Xie Ling, Shen Long-Shu, He Ya-Min, Zhu Chang-Le

出版信息

Zhonghua Bing Li Xue Za Zhi. 2005 Nov;34(11):745-6.

PMID:16536324

Abstract

摘要

相似文献

[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].

Zhonghua Bing Li Xue Za Zhi. 2005 Nov;34(11):745-6.

EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.

Nat Clin Pract Oncol. 2006 Apr;3(4):170-1. doi: 10.1038/ncponc0476.

Optimising therapy for EGFR-addicted NSCLC: just the start.

Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2. Epub 2012 Jan 26.

Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.

Clin Lung Cancer. 2005 Nov;7(3):163-5. doi: 10.1016/S1525-7304(11)70404-1.

Targeting EGFR in non-small-cell lung cancer.

N Engl J Med. 2005 Jul 14;353(2):200-2. doi: 10.1056/NEJMe058113.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

Erlotinib or gefitinib for non-small-cell lung cancer.

N Engl J Med. 2011 Jun 16;364(24):2367; author reply 2368. doi: 10.1056/NEJMc1103918.

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.

Korean J Intern Med. 2016 Nov;31(6):1140-1149. doi: 10.3904/kjim.2015.062. Epub 2016 Mar 28.

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.

Adv Ther. 2011 Feb;28(2):126-33. doi: 10.1007/s12325-010-0096-4. Epub 2010 Dec 16.

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30.